Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3

BJU International

Volumn 99, Issue 2, 2007, Pages 454-460

  Cheung, Catherine W ^a   Vesey, David A ^a,b   Nicol, David L ^a,b   Johnson, David W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Cell growth; DNA synthesis; Insulin like growth factor binding protein 3; Renal cell carcinoma; Silibinin; Viability; Western blotting

Indexed keywords

LACTATE DEHYDROGENASE; NEUTRALIZING ANTIBODY; SILIBININ; SOMATOMEDIN BINDING PROTEIN 3; THYMIDINE; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; CANCER INHIBITION; CELL COUNT; CELL DEATH; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG MECHANISM; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INCUBATION TIME; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; KIDNEY NEOPLASMS; SILYMARIN; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33846211547     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06571.x     Document Type: Article

References (30)

1. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000; 60: 5617-20
2. Feher J, Cornides A, Pal J, Lang I, Csomos G. Liver cell protection in toxic liver lesion. Acta Physiol Hung 1989; 73: 285-91
3. Zima T, Kamenikova L, Janebova M, Buchar E, Crkovska J, Tesar V. The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail 1998; 20: 471-9
4. Sonnenbichler J, Scalera F, Sonnenbichler I, Weyhenmeyer R. Stimulatory effects of silibinin and silicristin from the milk thistle Silybum marianum on kidney cells. J Pharmacol Exp Ther 1999; 290: 1375-83
5. Kuhlmann MK, Horsch E, Burkhardt G, Wagner M, Kohler H. Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin. Arch Toxicol 1998; 72: 536-40
6. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 1996; 11: 55-62
7. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 1999; 147: 77-84
8. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002; 62: 3063-9
9. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131-3
10. Russo P. Localized renal cell carcinoma. Curr Treat Options Oncol 2001; 2: 447-55
11. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 2006; 94: 614-9
12. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-90
13. Stassar MJ, Devitt G, Brosius M et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 2001; 85: 1372-82
14. Conover CA. Potentiation of insulin-like growth factor (IGF) action by IGF-binding protein-3: studies of underlying mechanism. Endocrinology 1992; 130: 3191-9
15. Pratt SE, Pollak MN. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994; 198: 292-7
16. Cheung CW, Vesey DA, Nicol DL, Johnson DW. The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation. Kidney Int 2004; 65: 1272-9
17. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-7
18. Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987; 56: 279-85
19. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77: 880-3
20. Rubin J, Chung LW, Fan X et al. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis. Prostate 2004; 58: 41-9
21. Kimura G, Kasuya J, Giannini S et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, PC-3 Cells. Int J Urol 1996; 3: 39-46
22. Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 2002; 51: 141-52
23. Zi X, Agarwal R. Modulation of mitogen-activated protein kinase activation and cell cycle regulators by the potent skin cancer preventive agent silymarin. Biochem Biophys Res Commun 1999; 263: 528-36
24. Agarwal C, Singh RP, Dhanalakshmi S et al. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003; 22: 8271-82
25. Koch HP, Bachner J, Loffler E. Silymarin: potent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol 1985; 7: 409-13
26. Wang L, Ma X, Yeh LC, Adamo ML. Differential regulation of IGF-binding protein gene expression by cAMP in rat C6 glioma cells. Endocrinology 2001; 142: 3917-25
27. Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 2004; 4: 1-11
28. Kim YC, Kim EJ, Lee ED et al. Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther 2003; 41: 593-6
29. Lorenz D, Lucker PW, Mennicke WH, Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984; 6: 655-61
30. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15: 465-89